First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Targeted therapy options for HER2-mutant non-small-cell lung cancer (NSCLC) were previously limited.
• Zongertinib is a novel oral tyrosine kinase inhibitor designed to selectively target HER2 while sparing wild-type EGFR.

Purpose of the Study:

• To evaluate the efficacy and safety of zongertinib in patients with advanced or metastatic HER2-mutant NSCLC.
• To assess zongertinib's activity in patients with active brain metastases.

Main Methods:

• A phase 1a-1b multicohort trial was conducted, focusing on zongertinib at 120 mg daily.
• Primary endpoint was objective response rate; secondary endpoints included duration of response and progression-free survival.
• Exploratory cohort assessed patients with active brain metastases.

Main Results:

• In previously untreated patients (n=74), the objective response rate was 76% (95% CI, 65-84), with a median progression-free survival of 14.4 months.
• In patients with brain metastases (n=30), the intracranial objective response rate was 47% (95% CI, 30-64).
• Treatment-related adverse events were predominantly low-grade, with 19% of patients experiencing grade 3 or higher events.

Conclusions:

• Zongertinib exhibits sustained efficacy in first-line treatment of HER2-mutant NSCLC.
• The drug was generally well-tolerated, with manageable adverse events.
• Zongertinib shows promise for patients with HER2-mutant NSCLC, including those with brain metastases.